NEW YORK, NY — November 5, 2025 — Leads & Copy —
Lexeo Therapeutics, Inc. (Nasdaq: LXEO) has provided business updates across its portfolio and reported its third quarter 2025 financial results. The FDA is open to pooling data from ongoing Phase I/II studies of LX2006 with data from a pivotal trial. The FDA approved a comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing the use of the Sf9 final commercial manufacturing process to begin dosing patients in an upcoming pivotal study.
LX2006 interim clinical data show improvements across cardiac and neurologic measures of Friedreich ataxia. Enrollment is complete for the LX2020 HEROIC-PKP2 Phase I/II trial with ten participants dosed. Lexeo closed a $154 million equity financing to support LX2006 activities and further development of its cardiac pipeline.
As of September 30, 2025, Lexeo’s cash, cash equivalents, and investments in marketable securities were $122.8 million. Research and Development expenses were $15.7 million for the three months ended September 30, 2025. The net loss was $20.3 million, or $0.33 per share, for the three months ended September 30, 2025.
Contact:
Carlo Tanzi, Ph.D.
ctanzi@kendallir.com
Media@lexeotx.com
Source: Lexeo Therapeutics, Inc.
